Blockchain Registration Transaction Record

Helus Pharma CEO to Present at Major Investment Conference

Helus Pharma CEO Michael Halstead to speak at H.C. Wainwright conference Sept 14. Clinical-stage company developing novel mental health treatments.

This news matters because it highlights Helus Pharma's active engagement with the investment community and the progress of its mental health treatments. For investors, the upcoming presentation offers an opportunity to gain insights into the company's strategy and clinical developments. For patients and healthcare providers, the advancement of novel serotonergic agonists like HLP003 and HLP004 could lead to new, more effective treatments for depression and anxiety, potentially improving outcomes for millions suffering from these conditions. The company's focus on neuroplasticity represents a promising frontier in psychiatric care.